Pfizer Stock Purchase Agreement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Nov. 09, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs					$ 49,744
Collaboration agreement revenue recognized		$ 802	$ 2,187	1,604	31,492
Pfizer Inc.
Common stock estimated fair value	$ 52,000
Stock purchase agreement remaining allocated value	8,000
Allocated Information Committee obligation	$ 8,000
Pfizer Inc. | Collaborative Arrangement
Collaboration agreement revenue recognized		800	$ 800	1,600	$ 1,600
Deferred revenue		$ 2,800		$ 2,800		$ 4,400
Private Placement
Issuance of common stock, net of discounts and issuance costs, Shares	5,000,000
Shares issued price per share	$ 12.00
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs	$ 60,000
Common stock purchase agreement condition	The shares of common stock sold to Pfizer were subject to a one-year lock-up from closing, during which time Pfizer was prohibited from selling or otherwise disposing of such shares.